195 related articles for article (PubMed ID: 12133398)
1. [Effect of rosiglitazone on insulin resistance and hyperandrogenism in polycystic ovary syndrome].
Zheng Z; Li M; Lin Y; Ma Y
Zhonghua Fu Chan Ke Za Zhi; 2002 May; 37(5):271-3. PubMed ID: 12133398
[TBL] [Abstract][Full Text] [Related]
2. Correction of insulin resistance and hyperandrogenism in polycystic ovary syndrome by combined rosiglitazone and clomiphene citrate therapy.
Shobokshi A; Shaarawy M
J Soc Gynecol Investig; 2003 Feb; 10(2):99-104. PubMed ID: 12593999
[TBL] [Abstract][Full Text] [Related]
3. Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations.
Koo YA; Shin SY; Yoon BK; Choi D
Gynecol Endocrinol; 2007; 23(8):461-7. PubMed ID: 17852414
[TBL] [Abstract][Full Text] [Related]
4. Metabolic and ovarian effects of rosiglitazone treatment for 12 weeks in insulin-resistant women with polycystic ovary syndrome.
Cataldo NA; Abbasi F; McLaughlin TL; Basina M; Fechner PY; Giudice LC; Reaven GM
Hum Reprod; 2006 Jan; 21(1):109-20. PubMed ID: 16155076
[TBL] [Abstract][Full Text] [Related]
5. Endocrine and metabolic effects of rosiglitazone in non-obese women with polycystic ovary disease.
Dereli D; Dereli T; Bayraktar F; Ozgen AG; Yilmaz C
Endocr J; 2005 Jun; 52(3):299-308. PubMed ID: 16006724
[TBL] [Abstract][Full Text] [Related]
6. The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome.
Yilmaz M; Biri A; Karakoç A; Törüner F; Bingöl B; Cakir N; Tiras B; Ayvaz G; Arslan M
J Endocrinol Invest; 2005 Dec; 28(11):1003-8. PubMed ID: 16483179
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome.
Diamanti-Kandarakis E; Kouli C; Tsianateli T; Bergiele A
Eur J Endocrinol; 1998 Mar; 138(3):269-74. PubMed ID: 9539300
[TBL] [Abstract][Full Text] [Related]
8. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome.
Kazerooni T; Dehghan-Kooshkghazi M
Gynecol Endocrinol; 2003 Feb; 17(1):51-6. PubMed ID: 12724019
[TBL] [Abstract][Full Text] [Related]
9. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome.
Dunaif A; Scott D; Finegood D; Quintana B; Whitcomb R
J Clin Endocrinol Metab; 1996 Sep; 81(9):3299-306. PubMed ID: 8784087
[TBL] [Abstract][Full Text] [Related]
10. The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome.
Yilmaz M; Bukan N; Ayvaz G; Karakoç A; Törüner F; Cakir N; Arslan M
Hum Reprod; 2005 Dec; 20(12):3333-40. PubMed ID: 16123091
[TBL] [Abstract][Full Text] [Related]
11. Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome.
Paradisi G; Steinberg HO; Shepard MK; Hook G; Baron AD
J Clin Endocrinol Metab; 2003 Feb; 88(2):576-80. PubMed ID: 12574183
[TBL] [Abstract][Full Text] [Related]
12. Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome.
Berria R; Gastaldelli A; Lucidi S; Belfort R; De Filippis E; Easton C; Brytzki R; Cusi K; Jovanovic L; DeFronzo R
Clin Pharmacol Ther; 2006 Aug; 80(2):105-14. PubMed ID: 16890572
[TBL] [Abstract][Full Text] [Related]
13. Rosiglitazone as treatment for clomiphene citrate-resistant polycystic ovary syndrome: factors associated with clinical response.
Shokeir T; El-Kannishy G
J Womens Health (Larchmt); 2008 Nov; 17(9):1445-52. PubMed ID: 18973428
[TBL] [Abstract][Full Text] [Related]
14. Metformin versus rosiglitazone in the treatment of polycystic ovary syndrome.
Mitkov M; Pehlivanov B; Terzieva D
Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):93-8. PubMed ID: 16360262
[TBL] [Abstract][Full Text] [Related]
15. Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance.
Sepilian V; Nagamani M
J Clin Endocrinol Metab; 2005 Jan; 90(1):60-5. PubMed ID: 15483106
[TBL] [Abstract][Full Text] [Related]
16. The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome.
Yilmaz M; Karakoç A; Törüner FB; Cakir N; Tiras B; Ayvaz G; Arslan M
Gynecol Endocrinol; 2005 Sep; 21(3):154-60. PubMed ID: 16335907
[TBL] [Abstract][Full Text] [Related]
17. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.
Pasquali R; Gambineri A; Biscotti D; Vicennati V; Gagliardi L; Colitta D; Fiorini S; Cognigni GE; Filicori M; Morselli-Labate AM
J Clin Endocrinol Metab; 2000 Aug; 85(8):2767-74. PubMed ID: 10946879
[TBL] [Abstract][Full Text] [Related]
18. Leptin concentrations in the polycystic ovary syndrome.
Mantzoros CS; Dunaif A; Flier JS
J Clin Endocrinol Metab; 1997 Jun; 82(6):1687-91. PubMed ID: 9177364
[TBL] [Abstract][Full Text] [Related]
19. Glucose intolerance, insulin resistance, and hyperandrogenemia in first degree relatives of women with polycystic ovary syndrome.
Yildiz BO; Yarali H; Oguz H; Bayraktar M
J Clin Endocrinol Metab; 2003 May; 88(5):2031-6. PubMed ID: 12727950
[TBL] [Abstract][Full Text] [Related]
20. Serum HLA-G levels in women with polycystic ovary syndrome.
Oztekin O; Fenkci SM; Fenkci V; Enli Y; Cabus U
Gynecol Endocrinol; 2015 Mar; 31(3):243-6. PubMed ID: 25403326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
